Evidence map›Paper›PMID 41950262›Full record

ArticlePLoS medicine2026

The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis.

Jiaying Stephanie Su, John Stover, Carel Pretorius, Peter Winskill, Sedona Sweeney, Timothy B Hallett, Nicolas A Menzies

Abstract read
In one paragraph

Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A model for the epidemiological impact of tuberculosis policy options.Bulletin of the World Health Organization · 2026
    Article
  2. ThemedRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiaying Stephanie SuDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0009-0002-4103-1893
John StoverAvenir Health, Glastonbury, Connecticut, United States of America.ORCID https://orcid.org/0000-0001-7236-1989
Carel PretoriusAvenir Health, Glastonbury, Connecticut, United States of America.ORCID https://orcid.org/0009-0007-9223-4013
Peter WinskillMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3001-4959
Sedona SweeneyDepartment of Global Health and Development, Faculty of Public Health Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0003-4233-9080
Timothy B HallettMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-9681-0424
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-2571-016X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlobal investments to combat HIV, tuberculosis, and malaria (HTM) have delivered substantial health gains and may have reduced the burden placed by these diseases on the routine health system. We estimated the reduction in primary healthcare (PHC) utilization resulting from the scale-up of HTM services over 2000-2023 in 108 low- and middle-income countries. METHODS AND

findingsFor each disease, we applied established mathematical models to quantify PHC utilization (outpatient visits and inpatient bed-days provided outside of HTM programs) by individuals with symptomatic HIV, tuberculosis, or malaria unable to access HTM-specific services. For each country, we estimated averted PHC utilization by comparing a scenario describing the actual scale-up of HTM services to a counterfactual scenario holding HTM service coverage constant at year 2000 levels. We applied published unit costs to estimate the averted costs resulting from reduced PHC utilization. Over 2000-2023, scale-up of HTM services averted an estimated 6.9 (95% uncertainty interval (UI) [4.4, 10.5]) billion outpatient PHC visits and 3.9 (95% UI [2.5, 5.9]) billion inpatient bed-days, representing US$135 (95% UI [71, 250]) billion in averted costs. These reductions were greatest in sub-Saharan Africa and East Asia and Pacific regions. Across study countries, these reductions represented a median of 4.4% of hospital bed capacity and 1.6% of government health spending in 2023. These percentages were 22.9% and 5.1%, respectively, for low-income countries. Our analysis did not consider changes in PHC services beyond utilization. Also, several inputs were missing in some countries, with missing values estimated using regression imputation.

conclusionsOver recent decades, sustained investments in HTM services in high-burden settings have averted substantial PHC utilization and associated costs. These benefits should be considered when assessing investment impact.

Indexed as

HIV InfectionsMalariaModels, EconomicPrimary Health CareTuberculosisCost-Benefit AnalysisHealth Care CostsHumans

Identifiers

PMID41950262
PMCPMC13061260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.